The company is an innovative biopharmaceutical enterprise mainly engaged in R&D, production and sales of recombinant protein drugs and microecological preparations. It focuses on treatment fields such as antiviral, tumor and immunity, hematology, digestion, degenerative diseases, etc., to build cutting-edge biotechnology platforms for novel proteins, novel antibodies, nucleic acid drugs, etc., adhere to the “innovation+internationalization” two-wheel drive platform-based development model, and explore the wide application of biotechnology in the field of health, actively cultivate and incubate new industries. It has now invested in cutting-edge fields such as animal vaccines and synthetic biology, and is committed to becoming a leader in biomedical biopharmaceutical services. Patients around the world. The company is an innovative international biopharmaceutical enterprise mainly engaged in the integration of R&D, production and sales of recombinant protein drugs and microecological preparations, focusing on treatment fields such as antiviral, tumor and immunity, blood, digestion, and degenerative diseases. The main products are Xeruojin injectable human interferon α1b, iprudine erythropoietin injection (CHO cells), Baitxi human granulocyte stimulating factor injection, Changlekang Clostridium butyrate diactive bacterial/capsule, proprietary Chinese medicine in ketone capsules, and segansu entecavir tablets. The company was recognized as “Shandong Provincial Enterprise Technology Center” in 2017, “Jinan Protein Drug Engineering Laboratory” in 2018, and “Guangdong Genetic Engineering Recombinant Protein Drug Engineering Technology Center”, “Shandong Protein Drug Engineering Laboratory” and “Shenzhen Postdoctoral Innovation Practice Base” in 2020. It was awarded the honorary title of “Jinan Green Factory” by the Jinan Municipal Bureau of Industry and Information Technology in Shandong Province.